Fundraising FoxNanoligent
Barcelona, ES · 2 known investors
Find your way into Nanoligent
Sign up to find every way you can get introduced to Nanoligent
- Your email: who you already know at Nanoligent, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Nanoligent team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Nanoligent is a biotech spin-off of the Universitat Autònoma de Barcelona and Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau that uses protein engineering and nanobiotechnology to develop targeted drug therapies, with a first cancer candidate targeting the CXCR4 receptor to limit tumor growth and metastasis. Its technology produces protein conjugates organized as nanoparticles for site-specific drug delivery aimed at oncology and potentially other disease biomarkers.
Founders & leadership
Investors · 2
Funding
SEC filings, press & company announcementsSource: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Nanoligent do?
- Nanoligent is a biotech spin-off of the Universitat Autònoma de Barcelona and Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau that uses protein engineering and nanobiotechnology to develop targeted drug therapies, with a first cancer candidate targeting the CXCR4 receptor to limit tumor growth and metastasis. Its technology produces protein conjugates organized as nanoparticles for site-specific drug delivery aimed at oncology and potentially other disease biomarkers.
- Who founded Nanoligent?
- Nanoligent was founded by Dr. A. Villaverde, Dr. E. Vázquez, Dr. R. Mangues, Dr. M. Rodríguez.
- Who are Nanoligent's investors?
- Nanoligent's investors include i&i Biotech Fund, Italian Angels for Growth.
- Where is Nanoligent headquartered?
- Nanoligent is headquartered in Barcelona, ES.